Loading...
XSTO
SPAGO
Market cap4mUSD
Dec 05, Last price  
0.11SEK
1D
0.90%
1Q
-55.36%
Jan 2017
-99.16%
IPO
-99.04%
Name

Spago Nanomedical AB (publ)

Chart & Performance

D1W1MN
XSTO:SPAGO chart
P/E
—
P/S
20.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
67.34%
Rev. gr., 5y
129.52%
Revenues
2m
+58.85%
981,000222,000228,00054,0007,515,00058,00047,00029,644,00030,000342,000660,0001,054,0001,203,0001,911,000
Net income
-33m
L-23.01%
-715,000-4,615,000-5,214,000-6,131,000-6,791,000-7,540,000-9,457,000-11,092,000-20,280,000-18,903,000-39,075,000-39,309,000-42,223,000-32,509,000
CFO
-35m
L-22.80%
-276,000-601,000-7,737,000-5,952,000-5,345,000-7,863,000-7,730,000-10,510,000-21,288,000-18,766,000-35,569,000-38,187,000-44,909,000-34,668,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Spago Nanomedical AB (publ) develops nanomedicines for cancer diagnostics and treatment primarily in Sweden. It is involved in the development of SN132D, a gadolinium-free MRI contrast agent for the treatment of breast and pancreas cancer under the SpagoPix project; and SN201, a radionuclide therapy for treatment of advanced and metastatic cancer under the Tumorad project. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
URL
https://spagonanomedical.se/
IPO date
Jan 15, 2013
Employees
13
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT